Document:

<PAGE>
                                                                   EXHIBIT 10.25

                              SECOND SIDE AGREEMENT

This Second Side Agreement ("Second Side Agreement"), retroactively effective as
of the 30th day of September, 2000 ("Second Side Agreement Effective Date"), is
by and between ACLARA BIOSCIENCES, INC., located at 1288 Pear Avenue, Mountain
View, California, 94043 ("Aclara") and PE CORPORATION (NY), having its Applied
Biosytems Group located at 850 Lincoln Center Drive, Foster City, California
94404 ("ABG"). Aclara and ABG will be referred to collectively as the "Parties."

                                   BACKGROUND

A.       Prior to this Second Side Agreement, Aclara and ABG have entered into
         five agreements relating to the development and commercialization of
         microfluidic technology in the field of High Throughput Screening:

         1. a Collaboration Agreement having an effective date of April 25, 1998
              (the "GA Agreement");

         2. a Custom Instrument Development And Commercialization Agreement
              having an effective date of October 1, 1998 (the "PRI
              Agreement");

         3. a Collaboration Agreement having an effective date of March 19, 1999
              (the "HTS Agreement");

         4. a Side Agreement having an effective date of March 19, 1999 (the
              "PRI Side Agreement"); and

         5. an Amendment To Collaboration Agreement having an effective date of
               March 20, 2001 (the "Caliper Amendment").

B.       The Parties wish to modify their contractual relations in the field of
         High Throughput Screening in order to facilitate Aclara's independent
         development of certain instrument systems and microfluidic devices.

NOW, THEREFORE, in consideration of the foregoing premises and the mutual
promises and covenants contained herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound, do hereby agree as follows:

                                        1

<PAGE>

                                    AGREEMENT

1.       NEW DEFINITIONS

1.1      DEFINITIONS. Any words with initial capitalization that are used in
         this Second Side Agreement that are not otherwise defined in this
         Second Side Agreement will have the meanings set forth in the HTS
         Agreement.

1.2      "Affiliates" has the meaning set forth at Section 1.1 of the HTS
         Agreement.

1.3      "Collaboration ACLARA Intellectual Property" has the meaning set forth
         at Section 1.4 of the HTS Agreement.

1.4      "Collaboration Field" has the meaning set forth at Section 1.20 of the
         HTS Agreement.

1.5      "Collaboration PERKIN-ELMER Intellectual Property" has the meaning set
         forth at Section 1.6 of the HTS Agreement.

1.6      "Exclusive Period" has the meaning set forth at Section 1.8 of the HTS
         Agreement.

1.7      "Existing Agreements" means the GA Agreement, the HTS Agreement, the
         PRI Agreement, the PRI Side Agreement, and the Caliper Amendment.

1.8      "High Throughput Screening" has the meaning set forth at Section 1.17
         of the HTS Agreement.

1.9      "Microfluidic Electrophoresis Device" has the meaning set forth at
         Section 1.21 of the HTS Agreement.

1.10     "Post Exclusive Period Product" means any Collaboration Product that is
         developed by Aclara or Aclara's Affiliate or licensee independently
         from ABG after the expiration of the Exclusive Period.

1.11     "Pre-Collaboration ACLARA Intellectual Property" has the meaning set
         forth at Section 1.3 of the HTS Agreement.

1.12     "PRI" means The R.W. Johnson Pharmaceutical Research Institute, a
         Division of Ortho-McNeil Pharmaceutical, Inc.

1.13     "Subject Patents" has the meaning set forth at Section 1.13 of the HTS
         Agreement.

                                        2

<PAGE>

2.       ACCELERATION OF THE EXCLUSIVE PERIOD

The Parties agree to alter the term of the Exclusive Period such that the
Exclusive Period will end upon the Second Side Agreement Effective Date. As
such, existing Section 1.8 of the HTS Agreement is hereby deleted and replaced
by the following:

         1.8      "Exclusive Period" means the term beginning on the Effective
                  Date and ending upon the Second Side Agreement Effective Date.

3.       REALLOCATION OF RESPONSIBILITIES

Certain responsibilities of the Parties with respect to the commercialization of
Post Exclusive Period Product are hereby clarified or altered from those set
forth in the HTS Agreement as follows:

(A)      for the sake of clarity, the Parties agree that the development and
         commercialization of the Post Exclusive Period Product will be excluded
         from the exclusivity provisions of Sections 3.2.1 and 3.3.1 of the HTS
         Agreement;

(B)      ABG grants to Aclara and its Affiliates a non-exclusive license, with
         the right to license third parties  through the sale of Post  Exclusive
         Period  Product or for the  purpose of  manufacture  of Post  Exclusive
         Period  Product,  under  Valid  Claims of Subject  Patents  which claim
         Collaboration   PERKIN-ELMER   Intellectual   Property  as   reasonably
         necessary to effect the use,  development and  commercialization of the
         Post  Exclusive   Period  Product  by  Aclara  and  its  Affiliates  or
         licensees,  as such non-exclusive license is set forth at Section 5.4.5
         of the HTS Agreement,  provided,  however,  any royalties  shall be due
         only with respect to Post Exclusive Period Product that is covered by a
         Valid Claim of a Subject Patent which claims Collaboration PERKIN-ELMER
         Intellectual Property;

(C)      ABG grants to Aclara and its Affiliates a non-exclusive, royalty-free
         license, with the right to license third parties, under Valid Claims of
         Subject Patents which claim Collaboration Joint Intellectual Property
         as necessary or useful to effect the use, development and
         commercialization of the Post Exclusive Period Product by Aclara and
         its Affiliates or licensees;

(D)      for the sake of clarity, nothing in this Second Side Agreement will
         restrict the rights of Aclara nor require Aclara to pay royalties with
         respect to claims of Subject Patents which claim Pre-Collaboration
         ACLARA Intellectual Property or Collaboration ACLARA Intellectual

         Property;

(E)      for the sake of clarity, the Parties agree that notwithstanding Section
         3.2.2 of the HTS Agreement, Aclara will be responsible for all expenses
         relating to the marketing, sales, and support of the Post Exclusive
         Period Product; and

                                        3

<PAGE>

(F)      notwithstanding Section 3.2.3 of the HTS Agreement, the Post Exclusive
         Period Product developed by Aclara will be marked so as to indicate
         that such product is a product of Aclara and/or its Affiliate or
         licensee alone, and not a product of ABG.

4.       PRI AGREEMENT

4.1      PAYMENTS FROM PRI. The Parties agree that any and all future payments
         by PRI under the PRI Agreement (including, without limitation, all
         payments that were accrued under Article 6 of the HTS agreement prior
         to or after the Second Side Agreement Effective Date but have not yet
         been paid by PRI) may, in Aclara's discretion, be made by PRI directly
         and solely to Aclara.

4.2      RIGHTS AND OBLIGATIONS. The Parties agree that, concurrently with this
         Second Side Agreement, the PRI Agreement will be separately amended in
         writing by the Parties and PRI such that (A) as an express condition to
         ABG's obligations under this Article 4, PRI shall grant to ABG a
         release in writing of all future obligations to PRI under the PRI
         Agreement except for ABG's confidentiality obligations thereunder and
         all such released obligations will be assumed solely by ACLARA, and (B)
         the PRI Agreement shall be amended with respect to ABG as of the Second
         Side Agreement Effective Date and all future rights of ABG under the
         PRI Agreement will accrue solely to Aclara.

5.       NO LICENSES

No license other than the licenses expressly set forth at Section 3(B) and 3(C)
of this Second Side Agreement is granted hereunder, whether express, implied, or
by estoppel, to any patent rights, or any other intellectual property rights,
owned, used, licensed to, or otherwise controlled by, ABG.

6.       CONTINUED FORCE AND EFFECT OF EXISTING AGREEMENTS

All provisions of the Existing Agreements, except as modified by this Second
Side Agreement, will remain in full force and effect and are hereby reaffirmed.
Other than as expressly stated in this Second Side Agreement, this Second Side
Agreement will not operate as a waiver of any condition or obligation imposed on
the Parties under the Existing Agreements.

                                        4

<PAGE>

7.       INTERPRETATION OF SECOND SIDE AGREEMENT

In the event of any conflict, inconsistency, or incongruity between any
provision of this Second Side Agreement and any provision of the Existing
Agreements, the provisions of this Second Side Agreement will govern and
control.

8.       ASSIGNABILITY

This Second Side Agreement and the licenses herein granted will be binding upon
and inure to the benefit of the successors in interest of the respective
Parties. Neither Party has the power to assign this Agreement nor any interest
hereunder without the written consent of the other Party; provided, however,
that either Party may assign this Agreement or any of its rights or obligations
to any Affiliate or to any third party with which it may merge or consolidate,
or to which it may transfer all or substantially all of its assets to which this
Agreement relates, without obtaining the consent of the other Party, subject to
such Affiliate or third party assuming all liabilities and obligations under
this Second Side Agreement.

9.       ENTIRE AGREEMENT

This Second Side Agreement, along with the Existing Agreements, constitute the
sole agreements between the Parties relating to the subject matter hereof and
supersede all previous writings and understandings. Neither Party has been
induced to enter into this Second Side Agreement by, nor is any Party relying
on, any representation or warranty outside those expressly set forth in this
Second Side Agreement.

10.      COUNTERPARTS

This Second Side Agreement may be executed in any number of counterparts, and
each counterpart will be deemed an original instrument, but all counterparts
together will constitute one agreement.

[Signature page follows.]

                                        5

<PAGE>

The Parties, through their authorized officers, have executed this Second Side
Agreement as of the Second Side Agreement Effective Date.

ACLARA BIOSCIENCES, INC.                 PE CORPORATION (NY), THROUGH
                                         ITS APPLIED BIOSYSTEMS GROUP

By:    /s/ Joseph M. Limber              By:    /s/ Michael W. Hunkapiller

Name:  Joseph M. Limber                  Name:  Michael W. Hunkapiller

Title: President and Chief Executive     Title: President Applied Biosystems
                                                Group, Executive Vice President,
                                                PE Corporation (NY)

Date:  October 15, 2001                  Date:  October 8, 2001
     ------------------------------           ------------------------------

                                        6<PAGE>

                                                                   EXHIBIT 10.26
                      Supply and Distributorship Agreement

This Agreement is entered into and effective as of October 26, 2001 ("Effective
Date"), by and between ACLARA BioSciences, Inc. having its principal place of
business at 1288 Pear Ave., Mountain View, CA 94043 ("ACLARA"), and Roche
Diagnostics Corporation, having its principal place of business at 9115 Hague
Road, Indianapolis, Indiana 46250 ("Roche"). Roche and ACLARA are collectively
referred to as "Parties" and individually as "Party".

WITNESSETH:

WHEREAS, Roche and its Affiliates are in the business of developing, making and
selling throughout the world various biochemical and medical products for
research, diagnostics, and other purposes.

WHEREAS, ACLARA is engaged in the business of developing microfluidic systems,
chips and chemistries which are also often referred to as "lab-on-chip"
technology.

WHEREAS, Roche desires to purchase, and be the exclusive distributor, and ACLARA
desires to sell to Roche and to appoint Roche as the exclusive distributor of
the Products (as defined herein) in accordance with the provisions of this
Agreement. In addition, Roche desires to acquire, and ACLARA desires to grant to
Roche, for a limited time period, exclusive first rights of refusal and the
right to negotiate to become a purchaser/licensee and the exclusive distributor
of certain Additional Products (defined below) developed by ACLARA.

NOW, THEREFORE, in consideration of the premises and the mutual covenants
contained herein and for good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, the Parties agree as follows:

1)       Definitions:

1.1 "Affiliate(s)" shall mean any other entity currently controlling, controlled
by or under common control with Roche or ACLARA, which in the case of Roche
shall include, without limitation, Roche Diagnostics GmbH. "Control" means that
more than fifty (50%) of the controlled entity's shares of ownership interest
representing the right to make decisions for such entity are owned or
controlled, directly or indirectly, by the controlling entity. An entity is
considered to be a related company only so long as such ownership or control
exists.

1.2 "Ordering Entity" shall mean an Affiliate or any other entity designated by
Roche and approved by ACLARA to purchase Product pursuant to the terms of this
Agreement.

Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as [*]. A complete version of this exhibit has been
filed separately with the Securities and Exchange Commission.

Confidential                        Page 1                               3/28/02

<PAGE>

1.3 "Products" shall mean ACLARA's Arteas-96 and Arteas-384 products, and
including all future or next generation versions of these Arteas-96 and
Arteas-384 products developed by ACLARA which are sub-microliter in scale and
incorporate means for evaporative compensation, packaged and labeled for Roche,
as detailed in the Specification which is attached hereto as Exhibit B, but
excluding any products which include means for separation of fluids or
compounds, including, without limitation, electrophoretic separation or
isoelectric focusing.

1.4 "Specification" shall mean the Roche specification for the Product attached
hereto and incorporated by reference as Exhibit B.

1.5 "Exclusive" status as a distributor or "Exclusive" shall mean that subject
to the terms and conditions of this Agreement, Roche's rights to market,
distribute and sell the Products within the Territory are sole and entire and
operate to exclude all others.

1.6      "Territory" shall mean worldwide.

1.7 "First Sales Year" shall mean the period commencing on the date of launch of
Product by Roche and ending one (1) year thereafter.

1.8 "FTEs" shall mean full time employee equivalents of labor, based on a
standard work day. One FTE shall be one person working one day, or eight hours
worked collectively by more than one person. One FTE for a year shall be one
person working each day in a year, exclusive of holidays and vacation time
determined in accordance with ACLARA's and Roche's, as the case may be,
customary practices and procedures. FTE's may be performed by employees,
consultants, contractors or other persons paid for by ACLARA or Roche.

1.9      As used above and in Section 6.15, the following terms shall mean:

         1.9.1    "Arteas [ * ] Product" means [ * ]

         1.9.2 "eTag Microfluidic Assay System" means [ * ]

         1.9.3    "Additional Products" shall singly or collectively refer to
                   [ * ]

2)       Confidential Information:

2.1 CONFIDENTIALITY OBLIGATIONS. For a period of [ * ] from the date of
disclosure, ACLARA and Roche agree to (i) hold all Confidential Information
(defined below) in trust and confidence for the disclosing party, (ii) not to
disclose Confidential Information to parties other than its Affiliates and
contractors or agents, and (iii) not to use such Confidential Information other
than for the performance of such Party or its Affiliates or

-----------------------------

[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 2

<PAGE>

contractors or agents under this Agreement. "Confidential Information" means (a)
information that relates to the disclosing party's past, present and future
efforts in research, development, manufacturing, and business activities that is
disclosed to or obtained by the receiving party in connection with, and during
the term of, this Agreement and (b) all items prepared or submitted by the
disclosing party that are the property of the other party under the terms of
this Agreement, including drafts and associated materials. All Confidential
Information shall be in written, graphic, photographic or other tangible form
and marked "Confidential", and information disclosed orally shall be confirmed
in written summary form marked "Confidential" within thirty (30) days after its
disclosure to the receiving party.

2.2 EXCEPTIONS. Any other provision hereof to the contrary notwithstanding, it
is expressly understood and agreed by the Parties hereto that the obligations of
confidence herein assumed shall not apply to any information which:

         a.     can be shown by the receiving  party to have been in its
                possession  prior to disclosure to it by the transmitting party;

         b.     at the time of the disclosure hereunder is, or thereafter
                becomes, through no fault of the receiving party, part of
                the public domain by publication or otherwise;

         c.     is furnished to the receiving party by a third party after the
                time of disclosure hereunder as a matter of right and
                without restriction on its disclosure; or

         d.     is independently developed by employees, agents or vendors of
                the receiving party who have not had access to the
                Confidential Information received from the disclosing party.

3)       Purchase Orders:

During the term of this Agreement, from time to time Roche (or the Ordering
Entity) may issue purchase orders containing instructions for specific
performance under this Agreement. Roche will accept only that specific
performance that has been pre-authorized, as evidenced by a purchase order, the
form and terms of which shall be mutually agreed (in the event of any
inconsistency between the terms of this Agreement and any purchase order, the
terms of this Agreement shall prevail). The purchase order number should always
be referenced on packing slips (bill of lading) and invoices for Product(s).

4)       Price:

4.1 The Parties agree that the price is as established in attached Exhibit A,
"Pricing". The Pricing detailed in Exhibit A shall represent the price terms
through the Initial Term of this Agreement. Subsequent to the Initial Term,
pricing shall be the result of good

                                     Page 3

<PAGE>

faith negotiations between the Parties.  Payment shall be due thirty (30) days
after receipt of invoice.

4.2 PROMOTIONAL ITEMS. ACLARA shall provide to Roche up to [ * ] Products per
year, on a schedule to be designated by Roche, at no charge for promotional
purposes. Promotional Products, not to exceed an additional [ * ] per year of
each, can be purchased at [ * ] of ACLARA's fully burdened Manufacturing Costs
for such promotional Products. "Manufacturing Costs" shall mean [ * ]

5)       Term and Termination:

5.1 INITIAL TERM AND EXTENSIONS. The "Initial Term" of this Agreement shall
begin on the Effective Date and shall continue for 3 years. Subsequent to the
Initial Term, this Agreement shall be automatically extended thereafter for one
(1) year periods unless notice of intention not to extend this Agreement is
communicated in accordance with Section 13.7 at least six (6) months prior to
the then current expiration date. Upon expiration of the Initial Term or any
subsequent one year extension term, ACLARA shall be entitled to (a) reasonable
termination charges for costs incurred up to the date of expiration by ACLARA
for outstanding orders of Product by Roche or other Ordering Entity, (b) share [
* ] in the course of its performance under this Agreement, (c) a transfer of all
rights in promotional materials, internet content, samples, customer lists, and
marketing material relating to Product which are developed by Roche and its
Affiliates in the course of its performance under this Agreement, (d) the right
to negotiate in good faith a world-wide license, with the right to sublicense,
to rights in trademarks used in connection with marketing and sale of Product,
and (e) the right to negotiate in good faith with Roche to obtain [ * ],
provided that ACLARA shall disclose such Confidential Information to any third
party under terms of confidentiality that are at least as strict as those
provided in Article 2 above.

5.2 TERMINATION FOR CAUSE. Either Party may terminate this Agreement for cause
by providing the other with sixty (60) days' written notice. Cause shall mean a
material breach of a material term of this Agreement, that is not cured by the
breaching party as quickly as possible, but in no event longer than the sixty
(60) day notice period. If such breach is not cured prior to the sixty (60) day
notice period, the non-breaching Party will be left with all remedies at law or
equity in addition to its right to terminate.

5.3 TERMINATION WITHOUT CAUSE. Commencing [ * ] after the Effective Date, Roche
reserves the right to terminate this Agreement without cause by providing [ * ]
written notice to ACLARA. For termination without cause, ACLARA shall be
entitled to (a) reasonable charges for costs incurred up to the date of
termination, (b) share [ * ] in the course of its performance under this
Agreement, (c) a transfer of all rights in promotional materials, internet
content, samples, customer lists, and marketing material relating to Product
which are developed by Roche and its Affiliates in the course of its

-----------------------------
[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 4

<PAGE>

performance under this Agreement, (d) the [ * ], and (e) the right to negotiate
in good faith with Roche to obtain [ * ], provided that ACLARA shall disclose
such Confidential Information to any third party under terms of confidentiality
that are at least as strict as those provided in Article 2 above.

5.4 IMPACT ON CONFIDENTIAL INFORMATION. Subject to the terms of Section 5.1
above, the Parties agree that in the event of termination or expiration of this
Agreement, all Confidential Information which is the property of Roche or
ACLARA, shall be promptly returned to the disclosing Party, except that one copy
thereof may be maintained in the file of the receiving Party's Law Department to
document information disclosed by the other Party.

6)       Supply Arrangements:

6.1 DILIGENCE OBLIGATIONS. Roche will maintain its right to be the exclusive
distributor of Product under this Agreement by its compliance with the following
diligence requirements set forth in Subsections 6.1.1 through 6.1.4 below. In
the event that Roche does not meet any of the following requirements, ACLARA at
its option, shall have the right to either convert Roche's distribution rights
from an exclusive to a non-exclusive status or provide notice of termination in
accordance with the terms of Section 5.2 above.

6.1.1    Within sixty (60) days after the Effective Date, the Parties shall
         agree upon, and attach to this Agreement, a detailed Work Plan,
         including Milestone Dates, for Roche's commercialization of Product,
         including both the Arteas-96 Product and the Arteas-384 Product,
         including, without limitation, sales training, technical support and
         assay support for miniaturization; and Roche shall use reasonable
         efforts to commercialize Product in accordance with the Work Plan and
         the Milestone Dates set forth therein.

6.1.2    The Parties  agree that the Work Plan for  commercialization  shall
         require Roche to commit the following  minimum  resources for Arteas-96
         Product and Arteas-384 Product:  one (1) marketing manager; and one (1)
         project manager (technical);  the marketing manager and project manager
         shall be part-time in calendar year 2001 and full time in calendar year
         2002 and thereafter.  Assay and technical  support will be available in
         the U.S. and Europe (with a Work Plan  supplement  for Japan),  and one
         hundred  percent  (100%) of the worldwide  key account  sales  managers
         (focused on  pharmaceutical  and biotech  companies) will be trained on
         Product.  During the First Sales Year,  ACLARA will miniaturize  assays
         for  Roche's  customers,  and will be  compensated  for  this  activity
         through  the  Transfer  Price  paid by  Roche  for  Product,  with  the
         mechanism  set forth in Section  6.4 below.  With  regard to the period
         after the First Sales Year,  the Work Plan will put in place a mutually
         agreed upon plan for assay  support  consistent  with actual  sales and
         projected sales growth.

--------------------------
[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 5

<PAGE>

6.1.3    During the First Sales Year, Roche shall use reasonable efforts to sell
         Product and its compliance with this diligence requirement shall be
         determined by its actual sales and reasonable penetration of Product
         into the High Throughput Screening market.

6.1.4    For each subsequent twelve-month period after the First Sales Year,
         Roche shall use reasonable efforts to sell Product and its compliance
         with this diligence requirement shall be determined by Roche generating
         [ * ]

6.2 EXCLUSIVITY OBLIGATIONS. The Parties agree that for the term of this
Agreement, and subject to the other terms and conditions set forth herein, (a)
ACLARA shall supply the Product exclusively to Roche and utilize Roche as its
exclusive distributor for the Products and (b) Roche shall not develop or sell
any other sub-microliter product including means for evaporative compensation
that directly competes with the Products for the drug screening market. Roche
shall purchase from ACLARA the Products at the prices set forth in Exhibit A to
this Agreement, attached hereto and incorporated herein by reference. Roche is
under no obligation to purchase a minimum quantity of Products except as
specifically set forth in Sections 6.1, 6.5, and 6.12 below during either the
Initial Term or any renewal term of this Agreement. [ * ]

6.3      TRANSFER OF EXPERTISE TO ROCHE.

         6.3.1 TRANSFER OF SALES/MARKETING EXPERTISE. Subject to the
         confidentiality terms above and to the terms of ACLARA's agreements
         with third parties regarding, among other matters, assays, dispensers
         and materials developed by the third parties and/or ACLARA, ACLARA
         will, at no additional cost to Roche, transfer to Roche its body of
         expertise that directly relates to sales and marketing of the Product,
         including expertise regarding use of the Product, customer
         segmentation, customer list, marketing materials, internet content,
         samples, presentations, sales tools, assay miniaturization, and
         qualifying dispensers , knowledge of which is instrumental to sales and
         marketing of the Product (collectively, the "Product Sales and
         Marketing Expertise"). This transfer will commence upon the execution
         of this Agreement and be completed within three (3) months of the
         Effective Date. Two (2) Roche employees will be designated by Roche to
         serve as primary representatives to receive the Sales and Marketing
         Expertise from ACLARA. ACLARA will provide these Roche representatives,
         at no charge to Roche, with any training at ACLARA's facilities that
         may reasonably be required in order for the Sales and Marketing
         Expertise to be effectively transferred to Roche. The transfer of Sales
         and Marketing Expertise will not be considered complete until all
         transferable, current assays have been transferred to Roche, and
         Roche's and ACLARA's primary representatives have determined, each in
         their reasonable discretion, that no other training or consultation
         with ACLARA representatives will be necessary in order for Roche to
         effectively sell, market and

----------------------
[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 6

<PAGE>

         use the transferred assays. ACLARA understands and agrees that
         successful transfer of the Sales and Marketing Expertise is
         instrumental to Roche's ability to sell the Product, and thus agrees it
         will use its reasonable commercial efforts to ensure all Sales and
         Marketing Expertise is transferred to Roche as expeditiously as
         possible.

         6.3.2 TRANSFER OF TECHNICAL/PRODUCT SUPPORT EXPERTISE. Subject to the
         confidentiality terms above and to the terms of ACLARA's agreements
         with third parties regarding, among other matters, assays, dispensers
         and materials developed by the third parties and/or ACLARA, ACLARA
         will, at no additional cost to Roche, transfer to Roche its entire body
         of expertise that directly relates to technical support or use of the
         Product, including expertise regarding developing miniaturized
         homogeneous assay and qualifying dispensers (collectively, the
         "Technical Support Expertise"). ACLARA represents and warrants that
         ACLARA possesses a transferable body of Technical Support Expertise,
         and ACLARA will make reasonable efforts to transfer such expertise, in
         accordance with this Section 6.3.2, such that Roche will be able to
         provide technical support and assistance relating to the Product at a
         level substantially similar to the support provided by ACLARA during
         the First Sales Year pursuant to Section 6.4. This transfer will
         commence upon the date for such transfer appearing in the Work Plan and
         be completed within twelve (12) months of such date. Two (2) Roche
         employees will be designated by Roche to serve as primary
         representatives to receive the Technical Support Expertise from ACLARA
         (and these Roche representatives need not be the same representatives
         designated to receive the Sales and Marketing Expertise described in
         Section 6.3.1). ACLARA will provide these Roche representatives, at no
         charge to Roche, with any training at ACLARA's facilities that may
         reasonably be required in order for the Technical Support Expertise to
         be effectively transferred to Roche. The transfer of Technical Support
         Expertise will not be considered complete until all transferable,
         current assays have been transferred to Roche, and Roche's and ACLARA's
         primary representatives have determined, each in their reasonable
         discretion, that no other training or consultation with ACLARA
         representatives will be necessary in order for Roche to effectively
         manage, utilize and fully support the transferred assays. On or before
         twelve (12) months after the Effective Date, Roche will in good faith
         provide ACLARA in writing a list of items of expertise yet to be
         transferred and the Parties will agree in good faith to a plan for
         transfer of such items.

6.4 TECHNICAL SUPPORT. During the First Sales Year, ACLARA will provide support
and assistance to Roche for the development of miniaturized homogeneous assays
for use on the Products ACLARA shall be compensated for such support and
assistance through the Transfer Price as managed by an account ("Account") that
will track the ordered Arteas 96 Product other than the Initial Order according
to Transfer Prices set forth in Exhibit A. Every order by Roche to ACLARA of
Product shall credit this account with the number of Products ordered. Every
order by Roche to ACLARA for a single assay miniaturization project (involving
one homogeneous assay), for a potential or actual

                                     Page 7

<PAGE>

Roche customer, shall debit this Account [ * ] At the outset, the Account will [
* ]. Thereafter, [ * ]. Hence, as an example, [ * ]. ACLARA shall make
reasonable efforts to successfully complete all assay miniaturization projects.
However, part of the initial technology transfer from ACLARA to Roche will
include a description of what types of assays constitute reasonable model assays
for miniaturization. Both parties recognize that some potential customers may
request work on an unreasonably difficult, or even impossible, assay.

6.5      INITIAL PURCHASE OF ARTEAS-96.  Roche will make an initial purchase of
[ * ] of Arteas-96  Product at the pricing and  scheduling as defined in Exhibit
A. No initial purchase of any other Product will be required hereunder.

6.6      PURCHASE ORDERS.  Subject to Sections 6.10 and 6.12, Roche shall submit
purchase orders to ACLARA for the quantities of Products desired.  Such purchase
orders shall constitute the only authorization for ACLARA to provide Products to
Roche.

6.7 DELIVERY. ACLARA shall deliver the Products in the quantities and on the
dates specified in the delivery schedules to Roche's purchase orders, F.O.B.
(Indianapolis, Indiana), freight collect using Roche's designated freight
carriers, third party direct bill. The transfer price terms in this Agreement
contemplate that the manufacture of Products shall be made in the United States
and all shipments will be made to locations in the United States. Any shipments
to other countries or between other countries will require mutually agreed upon
adjustments of the transfer price terms of this Agreement; and unless otherwise
mutually agreed in writing, any brokers' fees, customs duties, value added taxes
and any freight, insurance, taxes or other costs which are not imposed on ACLARA
under the definition "FOB (place of shipment)" in INCOTERMS, will be the sole
responsibility of Roche.

6.8 CHANGES TO ORDERS. Roche shall have the right to make changes to purchase
order quantities and delivery dates provided said changes are in conformance
within the firm lead-time and forecasting terms as established under Sections
6.10 and 6.12.

6.9 DISASTER RECOVERY PLAN. In order to demonstrate supply risk management to
Roche, within six (6) months after the Effective Date of this Agreement, ACLARA
shall document and maintain a Roche disaster recovery plan ("Plan") which would
be implemented in the event of a significant or catastrophic event affecting the
supply of Products. As a provision of the Plan, the Parties shall agree upon
terms for ACLARA to grant to Roche a limited time period, non-exclusive,
royalty-free license to manufacture the Products or sublicense a mutually
agreeable third party to do the same to prevent an interruption in supply. Upon
such occurrence, ACLARA shall immediately provide to Roche written detailed
information and technical assistance sufficient for Roche or a third party to
manufacture the Products, including, but not limited to:

         1) approved raw material vendor list,

------------------------
[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 8

<PAGE>

         2) raw material specifications,
         3) quality control procedures and,
         4) detailed manufacturing instructions

         (collectively the "Detailed Manufacturing Instructions")

If ACLARA can resume supplying Products to Roche's requirements, Roche or a
third party shall discontinue manufacturing the Products following production
restart, where ACLARA warrants that ACLARA has the capacity and capability of
satisfying Roche's full demand for Products. In such case the manufacturing
license with Roche and any sublicense with a third party shall terminate and the
originals and all copies of Detailed Manufacturing Instructions shall be
promptly returned to ACLARA. Roche and any sublicensee shall hold all Detailed
Manufacturing Instructions as confidential information, defined in Section 2.

6.10 FIRM LEAD-TIME. Subject to the terms of Section 6.12, firm lead-time for
Products shall be negotiated in good faith, to be [ * ]. Roche may not affect
changes to purchase orders within firm lead-time without the consent of ACLARA.
Should ACLARA not have Products in the quantities ordered, ready for shipment on
the requested purchase order date, where Roche has provided the firm lead-time
stated above, and expedited freight is required by Roche to meet production
needs, ACLARA shall be financially responsible for any incremental shipping cost
associated with such expedited freight. Notwithstanding any terms of this
Section 6.10 or Section 6.12 to the contrary, if Roche wishes to place order(s)
for Product that would require ACLARA to have a manufacturing capacity [ * ],
the firm lead-time for any such order(s) shall be [ * ] and also Roche shall
provide a special forecast for such order(s) in advance of the time period
provided in Section 6.12.

6.11 AUDIT. Subject to the confidentiality provisions of Section 2 hereof,
ACLARA shall make its records and facilities involved in the manufacturing and
testing of the current Product and all future Products, available to Roche
personnel at reasonable and mutually convenient times (not to exceed once each
calendar year) during normal business hours for audit purposes and shall take
any reasonable actions required by Roche to facilitate such audit. ACLARA shall
address any issues Roche may have within a reasonable timeframe.

6.12 FORECASTS. In order to facilitate ACLARA's forward planning process for
Products, and to assist ACLARA in making certain decisions relative to inventory
of long lead time raw materials, starting at the commencement of the First Sales
Year, Roche shall provide prior to the last day of each quarter on an "as needed
" basis a non-binding forecast of its requirements for the Products for the
following four (4) quarters. If ACLARA determines that it has insufficient
capacity to meet the quantities stated in the forecast, ACLARA shall notify
Roche within thirty (30) days after the date of receipt of the forecast that
such condition exists, and will present recommendations regarding

---------------------
[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 9

<PAGE>

capacity changes to meet the forecast. In any event, after the First Sales Year,
Roche shall be obligated to place firm lead time orders (according to Section
6.10) for a given quarter of a total amount that is [ * ] of the forecasted
requirements for such quarter according to the forecast that is provided
immediately before that quarter ("Obligated Orders"). For example, [ * ]
Products for that second quarter. During the First Sales Year the Obligated
Orders for a given quarter shall be [ * ] of the most recent forecast for that
quarter. Always ACLARA shall use reasonable commercial efforts to fill orders
that exceed Obligated Orders.

6.13 VALIDATION OF SUB-MICROLITER DISPENSERS. At the Effective Date of this
Agreement, ACLARA has qualified two suppliers of sub-microliter dispensers that
have been validated for use with the Arteas-96 Product; such dispensers are (1)
[ * ] dispenser manufactured and sold as of the Effective Date by [ * ] and (2)
[ * ] dispenser manufactured and sold as of the Effective Date by [ * ].
Furthermore the Parties will also cooperate regarding the best technical and
business relationship with other suppliers of sub-microliter dispensers. Roche
will evaluate in good faith whether to enter into a co-marketing agreement with
liquid dispensing robot vendors.

6.14 AVAILABILITY OF THE ARTEAS-384 PRODUCT. ACLARA agrees to commit all
reasonable efforts consistent with the priority of ACLARA's other projects, in
order to assure the successful development of the Arteas-384 Product. The launch
is presently contemplated, based on ACLARA's current development schedule for
Arteas-384 Product, to occur [ * ]. If the Parties decide that an [ * ] (and
will also make appropriate changes to the Work Plan for Roche's launch and sales
of Arteas-384 Product).

6.15     RIGHTS OF NEGOTIATION FOR ADDITIONAL PRODUCTS.

         6.15.1 CONSIDERATION. In consideration of the rights granted to Roche
         by ACLARA pursuant to the following subsections of this Section 6.15,
         [* ] the Effective Date of this Agreement, Roche shall pay by wire
         transfer to ACLARA [ * ]. Both Parties will negotiate in good faith [
         *]. The Parties agree that, absent an agreement by both Parties to the
         contrary, the cost to Roche [ * ]. ACLARA will use reasonable efforts
         to complete the Workplan and will submit a written report of results [
         * ].

         6.15.2 NEGOTIATION RIGHTS. Both Parties recognize that ACLARA is
         developing proprietary technology(s) of interest to both Parties,
         specifically technology for Additional Products defined in 1.9, and the
         desire of both Parties to commercialize these Additional Products. In
         consideration of the fee set forth in Subsection 6.15.1, during a
         period [ * ] agrees that Roche will be given the exclusive first rights
         of refusal and the right to negotiate [ * ].

         6.15.3   EXPANSION.  During the [ * ], ACLARA will also discuss
         expanding rights [ * ].

----------------------
[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 10

<PAGE>

7)       CHANGES:

7.1 CHANGES BY ROCHE. Roche reserves the right to propose changes to the Product
or to the Specifications and ACLARA shall not unreasonably withhold its approval
of such changes to the Product or Specification. Upon receiving such written
request from Roche, supplier shall submit within a reasonable time, but in no
event longer than 90 days, a report to Roche setting forth its best judgment as
to the probable effect on the supply of the Product and the cost of the proposed
change. If the changes would result in any significant increase in manufacturing
costs and/or in a significant development effort by ACLARA, the Parties shall
negotiate in good faith an increase of the transfer price terms for the Product
as so changed. In any event, ACLARA shall not proceed with any change that would
affect form, fit or function without written authorization from Roche, which
authorization Roche shall not unreasonably withhold.

7.2 CHANGES BY ACLARA. ACLARA must have written authorization from Roche (which
authorization Roche shall not unreasonably withhold) prior to incorporating any
change into production that may effect the form, fit, function, reliability,
product labeling, appearance, or interchangeability of any Product furnished to
Roche or its Affiliates. Changes incorporated by ACLARA's vendors /
manufacturers / contractors / subcontractors are also included in the
requirement. Shipments incorporating such changes will not be made until
authorization is obtained by Roche's Source Development Group at the receiving
location (which authorization Roche shall not unreasonably withhold). ACLARA is
to maintain control records documenting the effective dates, lot numbers, and/or
serial numbers of all engineering and process changes. The document control
system must ensure that obsolete drawings and specifications are removed from
all areas of use.

7.3 NEW PRODUCT . Should either Party wish to pursue an opportunity for
development and commercialization of a new Product that differs substantially
from the Arteas-96 Product and Arteas-384 Product ("New Product"), [ * ]

8)       WARRANTIES:

8.1 PRODUCT QUALITY; INDEMNIFICATION. ACLARA expressly warrants that all
Products furnished under this Agreement shall conform to all Specifications,
will be free from manufacturing defect(s). This warranty shall apply for a
period of [ * ] following date of manufacture of Products by ACLARA or its
contractor, unless otherwise expressly provided for herein. Roche agrees to
inspect Product upon its receipt and notify ACLARA, in writing within fifteen
(15) days after receipt, of Products that do not conform to Specifications
("Nonconforming Product"). ACLARA and Roche will agree upon a Replace of
Material Authorization Program (RMA Program") under which ACLARA would be
obligated to promptly correct, repair or replace Nonconforming Product, in
accordance with industry best practices. In accordance with the RMA

------------------------

[ * ]
Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

                                     Page 11

<PAGE>

Program, ACLARA will make corrections, repairs or replacements necessary to cure
breach of this warranty, provided, however, that (a) ACLARA reserves the right
to inspect and test, at its own cost, any Nonconforming Product; (b) the
Nonconforming Product has not been altered, repaired, or modified without the
prior approval of ACLARA; (c) the Nonconforming Product has not been damaged as
a result of accident, disaster, abuse, misuse, lack of maintenance or damage
during shipment and/or storage. ACLARA agrees to reimburse Roche for such
activity provided that such activity is consistent with the RMA Program or Roche
has received prior authorization to do so from ACLARA and abides by any
conditions agreed upon by ACLARA and Roche with respect to such actions. To the
extent that Roche is not able, or authorized to make said corrections, repairs
or replacements, ACLARA will perform same within thirty (30) days or such other
period provided in the RMA Plan, including replacement parts, labor,
installation, etc., necessary to correct and meet the warranty.

ACLARA SPECIFICALLY DISCLAIMS, WITH RESPECT TO PRODUCT FURNISHED HEREUNDER, ALL
OTHER WARRANTIES, EXPRESSED OR IMPLIED, ANY WARRANTIES OTHER THAN THOSE
EXPRESSLY PROVIDED IN THIS SECTION 8.1, INCLUDING, BUT NOT LIMITED TO, THE
IMPLIED WARRANTIES OF MERCHANTABILTY AND FITNESS FOR A PARTICULAR USE.

8.2 ORDER FULFILLMENT. ACLARA agrees that ACLARA or its Affiliate or contractor
shall use all reasonable efforts to fill Roche's or an Ordering Entity's
purchase order in accordance with the lead-time specified in Sections 6.10 and
6.12.

8.3 TERM OF MANUFACTURING. Subject to the termination provisions above, ACLARA
warrants to Roche that it or contractor(s) will continue to manufacture and
offer the Products throughout the Initial Term of this Agreement. After such
date, ACLARA warrants to Roche that in the event that ACLARA elects to no longer
offer the Products as specified in Exhibit A, ACLARA shall provide Roche with at
least six (6) months prior notice of such intent, and allow Roche to order the
Products during such six (6) months. Notwithstanding any other terms of this
Agreement, ACLARA may, in its discretion, fulfill its obligations under this
Agreement to supply Product by contracting manufacture thereof to a third party
contractor(s) approved by Roche, which approval(s) shall not be unreasonably
withheld.

8.4 RECALLS. As used herein, "Initiated Recall" shall mean a recall (a)
initiated at the direction of the Federal Food and Drug Administration or other
regulatory authority, arising out of, based on, or caused by defects in
materials or workmanship, improper manufacture of the Products, or failure of
the Products to meet the Specifications; or (b) initiated voluntarily by either
Party where evidence indicates that defects in materials or workmanship,
improper manufacture of the Products, or failure of the Products to meet the
Specifications warrants such a recall. Each Party shall promptly notify the
other Party of any situation which may lead to an Initiated Recall of the
Products, however, Roche and ACLARA shall have joint authority as to whether to
institute a voluntary recall. Roche shall notify ACLARA, in writing, if it is
required to implement a total or

                                     Page 12

<PAGE>

partial Initiated Recall. Both Parties agree to work together to properly manage
an Initiated Recall, foremost in terms of urgency and safety for the end
customer, and secondly for the efficient utilization of resources to accomplish
such Initiated Recall. The costs of any total or partial Initiated Recall shall
be allocated as follows, regardless of whether it was recalled by ACLARA, Roche,
or a governmental or regulatory authority: (a) if the defects or problems giving
rise to the reason for the Initiated Recall can reasonably be deemed to be the
direct result of negligent or willful acts or omissions on the part of ACLARA,
ACLARA shall bear the out-of-pocket costs and expenses associated with the
Initiated Recall; (b) if the defects or problems giving rise to the reason for
the Initiated Recall can reasonably be deemed to be the direct result of
negligent or willful acts or omissions on the part of Roche, Roche shall bear
the out-of-pocket costs and expenses associated with the Initiated Recall; (c)
if the defects or problems giving rise to the reason for the Initiated Recall
can reasonably deemed to be the direct result of negligent or willful acts or
omissions by both Parties, each Party will bear a portion of the out-of-pocket
costs and expenses roughly commensurate with its proportional responsibility for
the Initiated Recall, and (d) if it cannot reasonably be determined which party
was responsible for the defects or problems giving rise to the reason for the
Initiated Recall, then the Parties shall equally share the out-of-pocket costs
and expenses associated with the Initiated Recall.

9)       QUALITY:

9.1 RECORDS. In compliance with its own internal quality systems, each Party
shall keep reproducible records of all data pertaining to its performance under
this Agreement.

9.2 REVIEW OF RECORDS. Upon thirty (30) days prior written, each Party shall
make its records and facilities involved in the performance of this Agreement
available to the other Party's personnel at reasonable and mutually convenient
times during normal business hours for quality system audit purposes and shall
take any reasonable actions required by the reviewing Party to facilitate such
audit.

9.3 ISO 9001 CERTIFICATION. ACLARA, and all manufacturing facilities involved in
the production of the Product, agree to be ISO certified on the effective date,
or, if not, to actively pursue such certification during the term of this
Agreement. Until such time ISO certification is obtained, ACLARA will make
available all quality test procedures to Roche, in order for Roche to meet
current corporate ISO standards.

9.4 SAMPLES. For purposes of quality control testing and approval by Roche,
ACLARA shall upon request supply to Roche [ * ] Arteas-96 Product (and
Arteas-384 Product when commercially available) within two (2) weeks of
notification. During each 12-month period of the Agreement, additional
quantities [ * ] of Arteas-96 Product (and Arteas-384 Product when commercially
available) will be supplied [ * ] of ACLARA's fully burdened Manufacturing Costs
(as defined in Section 4.2), therefor.

------------------
[*] Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 13

<PAGE>

9.5      NON-CONFORMING PRODUCT.  Any Nonconforming Product at the customer site
         may be  replaced  in  accordance  with  the  terms  of the RMA  Plan as
         provided in Section 8.1 above.

10)      INDEMNIFICATION:

10.1     THIRD PARTY INFRINGEMENT:

         10.1.1 PATENT INDEMNIFICATION. Each Party ("Provider") will defend and
         indemnify the other Party ("Recipient") against a claim that any
         information, design, specification, instruction, software, data or
         material furnished by the Provider (collectively, "Material") and used
         by the Recipient infringes a patent held by a party other than ACLARA,
         Roche or their Affiliates ("Third Party Patent") provided that (a) the
         Recipient notifies the Provider in writing within five (5) business
         days of its knowledge of the claim; (b) the Recipient gives Provider
         sole control of the defense and all related settlement negotiation; and
         (c) the Recipient provides the Provider with the assistance,
         information and authority reasonably necessary to perform the above;
         reasonable out-of-pocket expenses incurred by the Recipient in
         providing such assistance will be reimbursed by the Provider. The
         Provider shall have no liability for any claim of infringement
         resulting from (i) the Recipient's use of a superseded or altered
         release of some or all of the Material if infringement would have been
         avoided by the use of a subsequent unaltered release of the Material
         which is provided to the Recipient; or (ii) any information, design,
         specification, instruction, software, data or material not furnished by
         the Provider.

         10.1.2 REMEDY FOR INDEMNIFICATION. In the event that some or all of the
         Material is believed by the Provider or is held to infringe a Third
         Party Patent, Provider shall have the option, at its expense, (a) to
         modify the Material to be non-infringing; (b) to obtain for the
         Recipient a license to continue using the Material; or (c) to require
         return of the infringing Material and all rights thereto from the
         Recipient. If ACLARA is the Provider and it elects option (c) above and
         such return materially affects Roche's ability to use the Material,
         Roche shall notify ACLARA in writing concerning the infringement.
         ACLARA shall have sixty (60) days to remedy said infringement. If
         ACLARA is unable to remedy, Roche may, at its option and upon sixty
         (60) days prior written notice to ACLARA, require ACLARA to return to
         Roche all amounts paid by Roche to ACLARA under this Agreement, limited
         to the amount of Roche's actual damages for infringement of the Third
         Party Patent. If Roche is the Provider and it elects option (c) above
         and such return materially affects ACLARA's ability to complete its
         performance under this Agreement, Roche shall have sixty (60) days to
         remedy such infringement. If Roche is unable to remedy, ACLARA may at
         its option and upon sixty (60) days prior written notice to Roche,
         terminate this Agreement, and Roche shall pay ACLARA for all services
         rendered and costs incurred in performance of its obligations under
         this Agreement from the Effective Date of this Agreement through the
         date of termination on a time and

                                     Page 14

<PAGE>

         materials or percent of completion basis as applicable, limited to the
         amount of ACLARA's actual damages for infringement of the Third Party
         Patent.

         10.1.3 EXCEPTIONS. Notwithstanding any terms of this Section 10.1 to
         the contrary, ACLARA's obligations to defend and indemnify under
         Subsection 10.1.1 and to return amounts paid by Roche under Subsection
         10.1.2 shall only apply to the extent that any claim of patent
         infringement relates to the use, manufacture or sale of the Product
         itself as such Product was actually manufactured by ACLARA for Roche.
         For example, without limiting the foregoing, in no event shall ACLARA
         have any liability under this Section 10.1 for any claim of
         infringement relating to assays, methods or compositions which may be
         utilized together with the Product, including, among others, any assays
         that it may have transferred to or developed for Roche pursuant to
         Section 6.3 or 6.4 above.

10.2     LIABILITY:

         10.2.1 LIABILITY OF ACLARA. ACLARA shall indemnify, defend and hold
         Roche harmless from any and all claims, demands, actions and causes of
         action against Roche in connection with any and all injuries, losses,
         damages or liability of any kind whatsoever (except for indirect or
         consequential damages) that is directly attributable to breach by
         ACLARA and its Affiliates and contractors of their obligations under
         this Agreement. This indemnification obligation shall include, without
         limiting the generality of the foregoing, reasonable attorneys' fees
         and other costs or expenses incurred in connection with the defense or
         settlement of any and all claims, demands, actions or causes of action.
         ACLARA's obligations hereunder to defend and indemnify are subject to
         the conditions that Roche promptly notifies ACLARA of any such claim or
         demand and permit ACLARA to have sole control the defense and
         settlement thereof.

         10.2.2 LIABILITY OF ROCHE. Roche shall indemnify, defend and hold
         ACLARA harmless from any and all claims, demands, actions and causes of
         action against Roche in connection with any and all injuries, losses,
         damages or liability of any kind whatsoever (except for indirect or
         consequential damages) directly attributable to the breach by Roche or
         its Affiliates of their obligations under this Agreement or to the sale
         of Product or use by third parties of Product that is sold by Roche or
         its Affiliates under this Agreement. This indemnification obligation
         shall include, without limiting the generality of the foregoing,
         reasonable attorneys' fees and other costs or expenses incurred in
         connection with the defense or settlement of any and all claims,
         demands, actions or causes of action. Roche's obligations to defend and
         indemnify is subject to the conditions that ACLARA promptly notifies
         Roche of any such claim or demand and permit Roche to have sole control
         the defense and settlement thereof.

11)      FORCE MAJEURE:

                                     Page 15

<PAGE>

Except as otherwise provided in this Agreement, each of the Parties hereto shall
be excused from the performance of its obligations thereunder in the event such
performance is prevented by force majeure and such excuse shall continue as long
as the condition constituting such force majeure continues, plus thirty (30)
days after the termination of such condition. For the purpose of this Agreement,
force majeure is defined as follows: Causes beyond the control of ACLARA or
Roche, including, but without limitation, regulations, laws or acts of any
government, destruction of ACLARA's facilities or material by fire, or failure
of public utilities or common carrier or embargo.

12)      INSOLVENCY:

Either Party may, at its option, terminate this Agreement upon thirty (30) days'
prior written notice without liability in the event of:

         a) Insolvency of the other Party or,
         b) Voluntary filing of petition for bankruptcy by the other Party, or
         c) Any filing of involuntary bankruptcy against the other Party, or
         d) Appointment of receiver or trustee for the other Party, or
         e) An assignment for the benefit of the other Party's creditors, or
         f) Any other act for the protection of debtors is filed by or against
            either Party.

For purposes of this Agreement, a Party is "insolvent" who either has ceased to
pay its debts in the ordinary course of business or cannot pay its debts as they
become due or is insolvent within the meaning of the federal bankruptcy law.

13)      GENERAL PROVISIONS:

13.1 ASSIGNABILITY. Each Party shall have the right to assign this Agreement or
its obligations hereunder to its Affiliates or any third party who obtains
Control of such Party. As used in this Section 13.1, "Control" means the
acquisition of a majority of the outstanding voting securities of the Party.

13.2 SURVIVABILITY. The rights and obligations of Section 2 (Confidentiality),
Section 8 (Warranties), Section 5 (Term and Termination), Section 10
(Indemnification) and Section 13 (General Provisions) shall survive any
termination of this Agreement and shall bind the Parties and their legal
representatives, successors, and assigns.

13.3 ENTIRE AGREEMENT. This Agreement embodies the entire understanding and
agreement among the Parties and supersedes all previous negotiations,
representations, writings and agreements, written, or oral, with respect to the
subject matter herein. Any additional terms or conflicting terms or conditions
contained in any other document pursuant to the subject matter herein are hereby
abrogated. ACLARA and Roche agree that this Agreement shall not be altered,
amended or modified, except in writing that is signed by an authorized
representative of both Parties.

                                     Page 16

<PAGE>

13.4 NON-WAIVER. No term or provision hereof shall be deemed waived and no
breach excused unless such waiver or consent shall be in writing and signed by a
duly authorized representative of the Party claimed to have waived or consented.

13.5 SEVERABILITY. If any provision of this Agreement is invalid or
unenforceable under any statute or rule or law, the provision is to that extent
to be deemed omitted, and the remaining provisions shall not be affected in any
way.

13.6     RELATIONSHIP OF THE PARTIES:

         13.6.1 ACLARA and Roche intend that an independent contractor
         relationship shall be created by this Agreement, and nothing herein
         shall be construed as creating an employer/employee relationship,
         partnership, joint venture, or concerted action.

         13.6.2 Personnel assigned by either Party to provide deliverables under
         this Agreement will be employees or contractors of said Party and will
         not for any purpose be considered employees or agents of the other
         Party. Each Party assumes full responsibility for the actions of such
         personnel and contractors while performing all its obligations
         hereunder, either at ACLARA or Roche facility, and shall be solely
         responsible for their supervision, daily direction and control, payment
         of salary (including withholding of income taxes and social security),
         workmen's compensation and occupational disease insurance as required
         by law, comprehensive public liability insurance, compensation,
         disability benefits and the like.

         13.6.3 ACLARA agrees that, while its personnel or contractors are on
         Roche's premises, they will conform to all Roche's work rules, safety
         regulations and its standard practices governing behavior of its own
         employees. Also, ACLARA agrees to require such personnel and
         contractors to work in a manner which will comply with all federal,
         state and local laws and regulations governing said work practices.

13.7 NOTICES. All notices, demands and communications provided for in this
Agreement shall be in writing and shall be deemed effective by a Party upon hand
delivery or when mailed, postage prepaid, by registered or certified mail, to
the other Party or its copy designee at the respective addresses listed below,
unless and until such address is changed by giving written notice thereof in
like manner.

         To Roche:         Roche Diagnostics Corporation
                           9115 Hague Road
                           Indianapolis, IN 46250
                           Attn: Purchasing Manager
                           (with a copy to the Law Department at the same
                           address)

         To ACLARA         ACLARA BioSciences, Inc.

                                     Page 17

<PAGE>

                           1288 Pear Avenue
                           Mountain View, CA 94043
                           Attn:  Joseph M. Limber, CEO and President
                           (with a copy to the Legal Department at the same
                           address)

13.8 EXPORT OF DATA. ACLARA agrees to comply with all applicable Federal, State
and local laws, regulations and ordinances, including but not limited to the
Regulations of the United States Department of Commerce relating to the Export
of Technical Data, insofar as they relate to the subject matter described
herein.

13.9     GOVERNING LAW:

         13.9.1 The Agreement shall be governed by the laws of the state of
         Delaware. Both Parties agree to use all reasonable efforts in a good
         faith attempt to settle as promptly as possible any and all disputes
         arising from this Agreement or a transaction conducted pursuant to this
         Agreement; but failing an amicable settlement, exclusive jurisdiction
         and venue over such dispute shall be in a court of competent
         jurisdiction residing in Marion County, Indiana or Santa Clara or San
         Francisco County, California.

         13.9.2 ACLARA and Roche shall do all things necessary to comply with
         all applicable Federal, State and local laws, regulations and
         ordinances relating to services to be performed under this Agreement.
         Roche and ACLARA are federal contractors with obligations from various
         Federal Laws, Code of Federal Regulations (CFR), Public Laws, and
         Executive Orders, such as Equal Employment Opportunity and the
         utilization of small, small disadvantaged, woman owned, veteran and HUB
         zone businesses per the Federal Acquisition Regulations (FAR). Each
         Party agrees to comply with the obligations contained in the applicable
         federal laws and regulations, as well as any applicable state or local
         laws or regulations of a similar nature. Each Party agrees to provide,
         at the other Party's request, any and all documentation required to
         substantiate such compliance.

13.10 PRODUCT MARKING. In the labeling and packaging inserts for Product, unless
the Parties otherwise mutually agree, Roche include the following reference:
"Developed and Manufactured by ACLARA BioSciences, Inc."

13.11 USE OF TRADEMARK AND NAME. Each Party may not use the other Party's name
or trademarks, or refer to or disclose the existence of this Agreement or the
obligations performed hereunder, directly or indirectly, without the prior
written consent of the other Party. If Roche wishes to use the Arteas trademark
in connection with its performance under this Agreement, it shall promptly
notify ACLARA and the Parties shall negotiate in good faith a separate license
agreement.

                                     Page 18

<PAGE>

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives.

Roche Diagnostics Corporation                       ACLARA BioSciences, Inc.

[illegible]                                 /s/ Joseph M. Limber
--------------------------------------      ------------------------------------
Name                                        Name

VP business Planning                        President, CEO
--------------------------------------      ------------------------------------
Title                                       Title

October 26, 2001                            October 26, 2001
--------------------------------------      ------------------------------------
Date                                        Date

--------------------------------------
Name

--------------------------------------
Title

--------------------------------------
Date

                                     Page 19

<PAGE>

                                    Exhibit A

                               Pricing - Arteas-96
                                       [*]

[ * ] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 20

<PAGE>

                                    Exhibit B

                           Products and Specifications

         1. Custom  packaged  Arteas-96  Product with Roche provided  labels and
            packaging materials.
         2. Custom packaged Arteas-384 Product with Roche provided labels and
            packaging materials.

                                  Arteas(TM) 96

                           Product Definition Document

PRODUCT DESCRIPTION

--------------------------------------------------------------------------------
Arteas(TM) Microfluidic Devices utilize a novel 96-channel design that enables
the miniaturization of biochemical assays to nanoliter volumes. Conventional
technology used to miniaturize assay volumes met with a range of unique problems
principally associated with evaporation. Now the Arteas device solves these
challenges by overcoming evaporation issues with an elegant and proprietary
design.

--------------------------------------------------------------------------------

                   BENEFITS OF THE ARTEAS MICROFLUIDIC DEVICE
--------------------------------------------------------------------------------
|X|      Controls evaporation while maintaining sample integrity at nanoliter
         volumes

|X|      Ensures proper mixing at nanoliter volumes
|X|      Enables assay CV ~10%
|X|      Allows library screening with previously impractical amounts of target
|X|      Decreases reagent usage up to 100 fold
--------------------------------------------------------------------------------

Physical Specifications

         1) Plate Materials

                a. Techmer 666 Black Styrene Resin
                b. Plasma Treated Trycite 3000 Film

         2) Dimensional Specifications
            A.  Overall

                a. Length       125.00 +/- 0.15mm

                                     Page 21

<PAGE>

                b. Height        14.50 +/-0.20mm
                c. Width         85.5  +/-    0.5mm
                d. Well Pitch     9.0 mm

            B.  Wells

                a. ECW (Evaporation Control Well)  2.0 mm (W) X 1.5 mm (H)
                b. AW  (Assay Well)                1.5 mm (W) X 1.5 mm (H)
                c. AR  (Auxiliary Reservoir)       2.0 mm (W) X 1.5 mm

Functional Specifications

(A summary of release data for Lots # AC121400 & #201 is available upon request)

            A. Fill Test

                  99.9% of the wells fill

            B. Test Compound Retention Test (Doc #1103, available on request)

                  To document the performance of the ArteasTM 96-pattern Card
                  when the Test Compound (using Fluorescein as a surrogate) is
                  pre-mixed and added via the Evaporation Control Well

                  Specification:
                  less than 80% Retention
                  % CV greater than 15% per plate

                  % CV greater than 15% (7 cards/group)

         C. Diffusion Test (Doc #1104 available upon request)

                  To determine the retention rate of fluorescein in the assay
                  wells of an ArteasTM Card

                  Specification:
                   less than 80% signal remaining in the Assay Well
                   % CV greater than 15% (6 cards/group)

         D. Stability Specification (Doc #1101 available on request)

                  To document product shelf life

                  Stability Specification:
                  One year from date of manufacture stored at room temperature
                  of between 19(Degree) C and 25(Degree) C

                                     Page 22

<PAGE>

                ACLARA will continue the stability studies to establish not less
                than eighteen (18) months stability.

         E. Functional Assay Data (Doc #1102 [Protease]; Doc #1111 [Alkaline
             Phosphatase]; Protocols available on request)

                  To perform functional assays for releasing commercial lots of
                  the ArteasDevice. Initial lots of Arteas 96 (Lot # AC121400 &
                  201) were released with the Cathepsin L protease assay. Future
                  lots manufactured will be released with the Alkaline
                  Phosphatase assay, which is currently in validation.

                  Specification:
                  % CV greater than 15% per card tested

                  z factor greater than  0.5

QUALITY ASSURANCE SAMPLING PLAN

         Production samples are tested according to the Manufacturer's Control
         Plan # 0001059. (Control Plan available on request).

            1.  Arteas-96 Leak Test Procedure/Specifications: 100% QC

                  Definition:
                  Before each leak test, vacuum is energized against a closed
                  valve and quantified (~ 28 in Hg). This value becomes the
                  `reference' vacuum value for each test. A `seal plate' is then
                  placed and sealed against the card skirt. Vacuum is drawn
                  against the card cavity where the film has been welded and
                  held for approximately 4 sec, after which a 2nd vacuum reading
                  is captured. If this 2nd vacuum reading is less than 95% of
                  the reference value, the card is considered to have failed the
                  test. A failed vacuum test means that air is flowing between
                  the film and the energy directors, indicative of a faulty
                  weld.

                  Specification:
                  Vacuum reading less than 95% of reference value

           2. Metrology Dimensional Testing

                  Parts are pulled every hour and dimensionally inspected
                  according to the Manufacturer's Control Plan.

           3. Functional Testing

Page 23

<PAGE>

     Parts are pulled every hour and functionally tested for % Fill, Test
     Compound Retention, Diffusion, and Functional Assay requirements.

PACKAGING REQUIREMENTS

         A.  Lot size               TBD

         B.  Packaging              TBD
                1.  Labeling
                2.  Container

                                 Arteas(TM) 384

                           PRODUCT DEFINITION DOCUMENT

Preliminary Product Description

         [ * ]

Physical and Functional Specifications

         [ * ]

-------------------
[ * ] Certain information on this page has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                     Page 24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00037-of-00352.parquet"}]]